Company Description
Century Therapeutics, Inc. engages in the development of off-the-shelf cell therapies to advance the course of cancer care. It engages in harnessing the power of adult stem cells to develop curative allogeneic cell therapies for cancer. The company was founded by Marcela Maus and Hiromitsu Nakauchi ...
Century Therapeutics, Inc. engages in the development of off-the-shelf cell therapies to advance the course of cancer care. It engages in harnessing the power of adult stem cells to develop curative allogeneic cell therapies for cancer. The company was founded by Marcela Maus and Hiromitsu Nakauchi in 2018 and is headquartered in Philadelphia, PA.
Valuation
Price to Book Ratio
2.20
Enterprise Value to EBITDA
-0.76
Enterprise Value to Sales
14.71
Efficiency
Liquidity
Current Ratio
14.57
Quick Ratio
14.57
Cash Ratio
14.24
Profitability
Return on Assets
-33.27
Return on Equity
-38.22
Return on Total Capital
-34.62
Capital Structure
Total Debt to Total Assets
5.74
Officers and Executives
Name | Age | Officer Since | Title |
---|---|---|---|
Mr. Joseph Jimenez | 60 | 2019 | Director |
Dr. Osvaldo Flores | - | - | Chief Executive Officer & Director |
Dr. Adrienne Farid | 59 | 2021 | Chief Operations Officer |
Insider Actions
08/09/2022 |
Versant Venture Management LLC |
364,800 | 0 | |
08/09/2022 |
Versant Venture Management LLC |
550,000 | Disposition at $13.03 per share. | 7,166,500 |
01/31/2022 |
Versant Venture Management LLC |
178,996 | 0 | |
12/23/2021 |
Versant Venture Management LLC |
371,004 | 0 | |
06/22/2021 |
Bayer AG |
750,000 | Acquisition at $20 per share. | 15,000,000 |
06/22/2021 |
Versant Venture Management LLC |
100,000 | Acquisition at $20 per share. | 2,000,000 |
06/22/2021 |
Eli Casdin Director |
750,000 | Acquisition at $20 per share. | 15,000,000 |
06/22/2021 |
Bayer AG |
1,535,238 | Derivative/Non-derivative trans. at $0 per share. | 0 |
06/22/2021 |
Bayer AG |
10,390,600 | Derivative/Non-derivative trans. at $0 per share. | 0 |
06/22/2021 |
Versant Venture Management LLC |
614,095 | Derivative/Non-derivative trans. at $0 per share. | 0 |
06/22/2021 |
Versant Venture Management LLC |
9,936,011 | Derivative/Non-derivative trans. at $0 per share. | 0 |
06/22/2021 |
FUJIFILM Holdings Corp. |
3,974,404 | Derivative/Non-derivative trans. at $0 per share. | 0 |
06/22/2021 |
Eli Casdin Director |
2,456,380 | Derivative/Non-derivative trans. at $0 per share. | 0 |
MarketWatch News on IPSC
-
Chardan Research initiates coverage of Century Therapeutics with a buy rating and $19 price target
-
Century Therapeutics started at overweight with $40 stock price target at J.P. Morgan
- Tomi Kilgore
-
Peter Thiel's Atai Life Sciences and 5 Other Companies List Shares
- Barron's Online
-
Century Therapeutics sets IPO terms; to offer 10.6 mln shares priced at $18 to $20 each
- Ciara Linnane
Other News on IPSC
-
10-Q: CENTURY THERAPEUTICS, INC.
- Edgar Online - (EDG = 10Q, 10K)
-
Athersys: Is Big Pharma Sleeping At The Wheel?
- Seeking Alpha
-
Century Therapeutics (IPSC) Investor Presentation - Slideshow
- Seeking Alpha
-
10-Q: CENTURY THERAPEUTICS, INC.
- Edgar Online - (EDG = 10Q, 10K)
-
Century Therapeutics (IPSC) Investor Presentation - Slideshow
- Seeking Alpha
-
10-Q: CENTURY THERAPEUTICS, INC.
- Edgar Online - (EDG = 10Q, 10K)
-
Company Corporate Overview Presentation Apr 2022
- Seeking Alpha
-
10-K: CENTURY THERAPEUTICS, INC.
- Edgar Online - (EDG = 10Q, 10K)
-
What's Behind Bristol Myers Squibb's Latest Partnership?
- Motley Fool
- Loading more headlines...